FierceBiotechOriginal article
{"a":[{"_":"Celldex ends skin disease program after failing phase 2 test","$":{"href":"/biotech/celldex-ends-work-skin-disease-after-failing-phase-2-test","hreflang":"en"}}]}
Phase 2negativebarzolvolimabNegative
AI Analysis
Summary
Celldex's phase 2 study of barzolvolimab in chronic skin disease missed its primary endpoint, leading the company to end development in the indication. The failure raises concerns about an upcoming eczema trial readout.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
missed primary endpoint
Importance:6/10
Sentiment:
-0.85
Phase 2 failureprogram discontinuationskin diseaseeczema
Related Companies
Read the original article
Published by FierceBiotech on July 22, 2026 5:11 AM